- Home
- ULH vs KROS Comparison
ULH vs KROS Comparison
Compare ULH & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULH
- KROS
- Stock Information
- Founded
- ULH 1932
- KROS 2015
- Country
- ULH United States
- KROS United States
- Employees
- ULH N/A
- KROS N/A
- Industry
- ULH Trucking Freight/Courier Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ULH Industrials
- KROS Health Care
- Exchange
- ULH Nasdaq
- KROS Nasdaq
- Market Cap
- ULH 618.7M
- KROS 565.0M
- IPO Year
- ULH 2005
- KROS 2020
- Fundamental
- Price
- ULH $19.04
- KROS $13.83
- Analyst Decision
- ULH Hold
- KROS Buy
- Analyst Count
- ULH 1
- KROS 14
- Target Price
- ULH $24.00
- KROS $20.56
- AVG Volume (30 Days)
- ULH 52.8K
- KROS 808.9K
- Earning Date
- ULH 10-23-2025
- KROS 11-05-2025
- Dividend Yield
- ULH 2.21%
- KROS N/A
- EPS Growth
- ULH N/A
- KROS N/A
- EPS
- ULH 2.31
- KROS 0.47
- Revenue
- ULH $1,668,148,000.00
- KROS $232,844,000.00
- Revenue This Year
- ULH N/A
- KROS $6,657.47
- Revenue Next Year
- ULH $5.57
- KROS N/A
- P/E Ratio
- ULH $8.24
- KROS $29.72
- Revenue Growth
- ULH N/A
- KROS 85820.30
- 52 Week Low
- ULH $18.40
- KROS $9.12
- 52 Week High
- ULH $53.29
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ULH 33.68
- KROS 32.69
- Support Level
- ULH $18.50
- KROS $15.50
- Resistance Level
- ULH $19.71
- KROS $16.44
- Average True Range (ATR)
- ULH 1.17
- KROS 0.69
- MACD
- ULH -0.22
- KROS -0.26
- Stochastic Oscillator
- ULH 13.06
- KROS 8.08
About ULH Universal Logistics Holdings Inc.
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.